Introduction
Postprandial reactive hypoglycaemia following gastric surgery is fortunately now rare but can be quite disabling to those affected. Conventional treatment by frequent small meals with increased fibre content and the addition of substances such as guar and pectin is generally unsuccessful. Previous reports of somatostatin infusions and subcutaneous administration of a long acting somatostatin analogue over short periods of time have demonstrated the effectiveness of this hormone in the management of this condition.`4 Our patient was treated with twice-daily subcutaneous injections of Sandostatin, a long acting somatostatin analogue5'6 for a period of 3 weeks and monitored as an out-patient. He derived good symptomatic and biochemical relief.
Case report
A 50 year old West Indian post-office worker, who had undergone a vagotomy and gastroenterostomy 15 years previously for chronic duodenal ulceration, was referred with a history of intermittent episodes of tremor and faintness occurring between 90 and 120 minutes following meals. These episodes, which were rapidly relieved by glucose, had become so frequent as to prevent him from working. Diarrhoea was not associated with the episodes and the patient had never lost consciousness. His symptoms had failed to respond to treatment with small frequent meals with a high fibre diet, guar gum granules and a reduced carbohydrate intake with each meal.
An extended oral glucose tolerance test showed a lag type storage curve with reactive hypoglycaemia; the lowest blood glucose recorded at 120 minutes was 1.9 mmol/I ( Figure 1 ). A 72 hour fast followed by exercise failed to reproduce hypoglycaemia. He was then reassessed using a mixed test breakfast containing 75 g of carbohydrate after an overnight fast. On the first occasion he was given a subcutaneous injection of normal saline before the breakfast and the blood glucose fell to 2.4 mmol/l at 150 minutes. On a subsequent morning he was given 50 ytg Sandostatin subcutaneously at the beginning of the meal. The minimum blood glucose of4.7 mmol/l occurred at 210 minutes and there was complete abolition of symptoms with resolution of the reactive hypoglycaemia. Fasting plasma insulin levels were comparable on the two test days, (normal saline: 11.7 mU/l, Sandostatin: 12.2 mU/l). The 60 minute value, however, was completely suppressed after Sandostatin (normal saline: > 500 mU/l, Sandostatin: 12.3 mU/l).
He was taught to self monitor blood glucoses using BM-glycaemie strips and to administer the subcutaneous injections himself. He was discharged on Sandostatin 50 pg twice daily with his breakfast and evening meal.
He was reassessed at weekly intervals and after 2 weeks the Sandostatin was administered 30 minutes after the test meal. This led to a smoother control of postprandial glucose (Figure 1 ). The patient's selfmonitored glucoses were normal whilst taking twice daily Sandostatin, but showed values of 2.0 mmol/l or less on discontinuing the treatment. There was an immediate return of reactive hypoglycaemic symptoms on cessation of Sandostatin.
The 24-hour faecal fat excretion while on the Sandostatin was 45 mmol/day and 2 weeks after discontinuing the injections the 24-hour faecal fat remained elevated at 45 mmol/day (normal < 18 mmol/day). 
Discussion
The main adverse effects of Sandostatin experienced by our patient included local irritation at the injection site, which was relieved by allowing the Sandostatin solution to warm to room temperature prior to injection, and a moderately painful burning sensation on defaecation associated with the passage of bulky pale stools. The latter sensation improved with time. The modestly elevated faecal fat excretion while on the Sandostatin remained unaltered on cessation of the injections. This suggests that there was a degree of malabsorption secondary to the original surgery; this is a common and well recognized phenomenon. 
